Human brain cholecystokinin: Release of cholecystokinin-like immunoreactivity (CCK-LI) from isolated cortical nerve endings and its modulation through GABAB receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 2, 1996, Pages 747-751

  Raiteri, Maurizio ^a,c   Bonanno, Giambattista ^a   Paudice, Paolo ^a   Cavazzani, Paolo ^b   Schmid, Giovanna ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b GALLIERA HOSPITAL   (Italy)

^c Istituto di Farmacologia e Farmacognosia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 3 AMINOPROPYL(DIFLUOROMETHYL)PHOSPHINIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; [3 (3,4 DICHLOROBENZYLAMINO)PROPYL](DIETHOXYMETHYL)PHOSPHINIC ACID; BACLOFEN; UNCLASSIFIED DRUG;

ANXIETY NEUROSIS; ARTICLE; BRAIN CELL; DEPOLARIZATION; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; HUMAN TISSUE; NERVE POTENTIAL; PRIORITY JOURNAL; PROTEIN SECRETION; SYNAPTOSOME; TRANQUILIZING ACTIVITY;

BENZYLAMINES; BRAIN; CALCIUM; CEREBRAL CORTEX; CHOLECYSTOKININ; DOSE-RESPONSE RELATIONSHIP, DRUG; GABA ANTAGONISTS; HUMANS; NERVE FIBERS; PHOSPHINIC ACIDS; RECEPTORS, GABA-B;

EID: 0030432247     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. ANDREWS, N. AND FILE, S. E.: Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur. J. Pharmacol. 235: 109-112, 1993.
2. B receptor-mediated release of GABA and glutamate in rat thalamic ventrobasal nucleus: A possible mechanism for the generation of absence-like seizures induced by GHB. J. Pharmacol. Exp. Ther. 273: 1534-1543, 1995.
3. BEINFELD, M. C.: Cholecystokinin/gastrin. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. J. Kupfer, pp. 585-594, Raven Press, New York, 1995.
4. BEINFELD, M. C., MEYER, D. K., ESKAY, R. L., JENSEN, J. T. AND BROWNSTEIN, M. G.: The distribution of cholecystokinin-immunoreactivity in the central nervous system of the rat, as determined by radioimmunoassay. Brain Res. 212: 51-57, 1981.
5. B receptors, inhibits the release of cholecystokinin-like material from the rat spinal cord in vitro. Brain Res. 590: 255-262, 1992.
6. BIGGIO, G. AND COSTA, E.: GABA and benzodiazepine receptor subtypes. Advances in Biochemical Psychopharmacology, vol. 46. Raven Press, New York, 1990.
7. B-type in human cerebral cortex. Br. J. Pharmacol. 96: 341-346, 1989.
8. B receptors. Trends Pharmacol. Sci. 14: 259-261, 1993.
9. B receptor pharmacology. Ann, Rev. Pharmacol. Toxicol. 33: 109-147, 1993.
10. BRADFORD, M. M.: Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 246-254, 1976.
11. BRADWEJN, J. AND DE MONTIGNY, C.: Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones. Nature (Lond.) 312: 363-364, 1984.
12. BRADWEJN, J., KOSZYCKI, D. AND SHRIQUI, C.: Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorders. Arch. Gen. Psychiatry 48: 603-610, 1991.
13. BRADWEJN, J., KOSZYCKI, D., CÖUETOUX DU TERTRE, A., BOURIN, M., PALMOUR, R. AND ERVIN, F.: The cholecystokinin hypothesis of panic and anxiety disorders: A review. J. Psychopharmacol. 6: 345-351, 1992.
14. BRESLOW, M. F., FRANKHAUSER, M. P., POTTER, R. L., MEREDITH, K. E., MISIASZEK, J. AND HOPE, D. J.: Role of gamma-aminobutyric acid in antipanic drug efficacy. Am. J. Psychiat. 146: 353-356, 1989.
15. BROG, J. S. AND BEINFELD, M. C.: Cholecystokinin release from the rat caudateputamen, cortex and hippocampus is increased by activation of the D-1 dopamine receptor. J. Pharmacol. Exp. Ther. 260: 343-348, 1992.
16. BURGUNDER, J. M. AND YOUNG, W. S. III.: The distribution of thalamic projection neurons containing cholecystokinin mRNA, using in situ hybridization histochemistry and retrograde labeling. Mol. Brain Res. 4: 179-189, 1988.
17. CONZELMANN, U., MEYER, D. K. AND SPERK, K.: Stimulation of receptors of γ-aminobutyric acid modulates the release of cholecystokinin-like immunoreactivity from slices of rat neostriatum. Br. J. Pharmacol. 89: 845-852, 1986.
18. CRAWLEY, J. N. AND CORWIN, R. L.: Biological actions of cholecystokinin. Peptides 15: 731-755, 1994.
19. DE MONTIGNY, C.: Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch. Gen. Psychiat. 46: 511-517, 1989.
20. EMSON, P. C., LEE, C. M. AND REHFELD, J. F.: Cholecystokinin octapeptide: Vesicular localization and calcium dependent release from rat brain in vitro. Life Sci. 26: 2157-2163, 1980.
21. B receptor. Eur. J. Pharmacol. 263: 311-314, 1994.
22. FILE, S. E., ZHARKOVSKY, A. AND HITCHCOTT, P. K.: Effects of nitredipine, chlordiazepoxide, flumazenil and baclofen on the increased anxiety resulting from alcohol withdrawal. Prog. Neuropsychopharmacol. Biol. Psychiat. 16: 87-93, 1992.
23. FREEMAN, A. S., CHIODO, L. A., LENTZ, S. I., WADE, K. AND BANNON, M. J.: Release of cholecystokinin from rat midbrain slices and modulatory effect of D-2 DA receptor stimulation. Brain Res. 555: 281-287, 1991.
24. B antagonists. Pharmacol. Comm. 2: 52-56, 1992.
25. B receptors regulating cholecystokinin and somatostatin release from rat neocortex synaptosomes. Mol. Pharmacol. 46: 558-562, 1994.
26. HARRO, J., VASAR, E. AND BRADWEJN, J.: CCK in animal and human research on anxiety. Trends Pharmacol. Sci. 14: 244-249, 1993.
27. HENDRY, S. H. C., JONES, E. G., DE FELIPE, J., SCHMECHEL, D., BRANDON, C. AND EMSON, P. C.: Neuropeptide containing neurons of the cerebral cortex are also GABAergic. Proc. Natl. Acad. Sci. U.S.A. 81: 6526-6530, 1984.
28. HINDERER, S. R.: The supraspinal anxiolytic effect of baclofen for spasticity reduction. Am. J. Phys. Med. Rehabil. 69: 254-258, 1990.
29. HÖKFELT, T., REHFELD, J. F., SKIRBOLL, L., IVEMARK, B., GOLDSTEIN, M. AND MARKEY, K.: Evidence for coexistence of dopamine and CCK in mesolimbicneurons. Nature 285: 476-478, 1980.
30. LINDEFORS, N., LINDEN, A., BRENE, S., SEDVALL, G. AND PERSSON, H.: CCK peptides and mRNA in the human brain. Prog. Neurobiol. 40: 671-690, 1993.
31. MEYER, D. K. AND KRAUSS, J.: Dopamine modulates cholecystokinin release in neostriatum. Nature (Lond.) 301: 338-340, 1983.
32. B receptors. Int. Rev. Neurobiol. 36: 97-223, 1994.
33. B receptors. Eur. J. Pharmacol. 187: 27-38, 1990.
34. 3 receptors in rat cerebral cortex and nucleus accumbens. Br. J. Pharmacol. 103: 1790-1794, 1991.
35. RAITERI, M.: Functional studies of neurotransmitter receptors in human brain. Life Sci. 54: 1635-1647, 1994.
36. RAITERI, M., ANGELINI, F. AND LEVI, G.: A simple apparatus for studying the release of neurotransmitters from synaptosomes. Eur. J. Pharmacol. 25: 411-414, 1974.
37. RAITERI, M., PAUDICE, P. AND VALLEBUONA, F.: Release of cholecystokinin in the central nervous system. Neurochem. Int. 22: 519-527, 1993.
38. RAVARD, S. AND DOURISH, C. T.: Cholecystokinin and anxiety. Trends Pharmacol. Sci. 11: 271-273, 1990.
39. REHFELD, J. F.: Immunochemical studies on cholecystokinin. I. Development of sequence-specific radioimmunoassays for porcine triacontatriapeptide cholecystokinin. J. Biol. Chem. 253: 4016-4021, 1978.
40. SAVASTA, M., PALACIOS, J. M. AND MENGOD, G.: Regional distribution of the messenger RNA coding for the neuropeptide cholecystokinin in the human brain examined by in situ hybridization. Mol. Brain Res. 7: 91-104, 1990.
41. SEROOGY, K. B., DANGARAN, K., LIM, S., HAYCOCK, J. W. AND FALLON, J. H.: Ventral mesencephalic neurons containing both cholecystokinin- and tyrosine hydroxylase-like immunoreactivities project to forebrain regions. J. Comp. Neurol. 279: 397-414, 1989.
42. SOMOGYI, P., HODGSON, A. J., SMITH, A. D., NUNZI, M. G., GORIO, A. AND WU, J.-Y.: Different populations of GABAergic neurons in the visual cortex and hippocampus of cat contain somatostatin- or cholecystokinin-immunoreactive material. J. Neurosci. 4: 2590-2603, 1984.
43. VALLEBUONA, F., PAUDICE, P. AND RAITERI, M.: Release of cholecystokinin-like immunoreactivity in the frontal cortex of conscious rats as assessed by transcerebral microdialysis: Effects of different depolarizing stimuli. J. Neurochem. 61: 490-495, 1993.
44. VANDERHAEGHEN, J. J., SIGNEAU, J. C. AND GEPTS, W.: New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature (Lond.) 257: 604-605, 1975.
45. VERHAGE, M., GHIJSEN, W. E. J. M., NICHOLLS, D. G. AND WIEGANT, V. M.: Characterization of the release of cholecystokinin-8 from isolated nerve terminals and comparison with exocytosis of classical transmitters. J. Neurochem. 56: 1394-1400, 1991.
46. WOODRUFF, G. N. AND HUGHES, J.: Cholecystokinin antagonists. Ann. Rev. Pharmacol. Toxicol. 31: 469-501, 1991.
47. YAKSH, T. L., FURUI, T., KANAWATI, I. S. AND GO, V. L. W.: Release of cholecystokinin from rat cerebral cortex in vivo: Role of GABA and glutamate receptor systems. Brain Res. 406: 207-214, 1987.